Logo
x

Search

Subscribe Now

Rhythm

Rhythm’s Imcivree (setmelanotide) Receives Health Canada Approval for Weight Management in Adult and Pediatric Patients with Obesity

Rhythm’s Imcivree (setmelanotide) Receives Health Canada Approval for Weight Management in Adult and Pediatric Patients with Obesi...

  • May 9, 2023
Rhythm Receives the US FDA’s Breakthrough Therapy Designation for Setmelanotide to Treat Hypothalamic Obesity

Rhythm Receives the US FDA’s Breakthrough Therapy Designation for Setmelanotide to Treat Hypothalamic Obesity

  • November 2, 2022
Insights+: EMA Marketing Authorization of New Drugs in September 2022

Insights+: EMA Marketing Authorization of New Drugs in September 2022

  • October 26, 2022
Rhythm’s Imcivree (setmelanotide) Receives EC’s Approval for the Treatment of Bardet-Biedl Syndrome

Rhythm’s Imcivree (setmelanotide) Receives EC’s Approval for the Treatment of Bardet-Biedl Syndrome

  • September 6, 2022
Rhythm’s Imcivree (setmelanotide) Receives NICE Recommendation for Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency

Rhythm’s Imcivree (setmelanotide) Receives NICE Recommendation for Obesity and Controlling Hunger Caused by POMC or LEPR Deficienc...

  • July 19, 2022
Rhythm Receives the US FDA’s Approval for Imcivree (setmelanotide) sNDA to Treat Bardet-Biedl Syndrome

Rhythm Receives the US FDA’s Approval for Imcivree (setmelanotide) sNDA to Treat Bardet-Biedl Syndrome

  • June 17, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.